Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Jul;72(1):76–81. doi: 10.1038/bjc.1995.280

AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo.

S R McKeown 1, M V Hejmadi 1, I A McIntyre 1, J J McAleer 1, L H Patterson 1
PMCID: PMC2034137  PMID: 7599069

Abstract

AQ4N (1,4-bis([2-(dimethylamino-N-oxide)ethyl]amino)5,8-dihydroxy- anthracene-9,10-dione) is a novel alkylaminoanthraquinone N-oxide which, on reduction, forms a stable DNA affinic cytotoxic compound AQ4. The in vivo anti-tumour efficacy of AQ4N was investigated in B6D2F1 mice bearing the T50/80 mammary carcinoma. The effect of the drug was evaluated in combination with hypobaric hypoxia and with radiation (single and multiple fractions). Systemic toxicity was assessed by weight loss post treatment. This was low for AQ4N and was less than that obtained with the bioreductive drugs, RSU 1069 (1-[3-aziridinyl-2-hydroxypropyl]-2-nitroimidazole) and SR 4233 (Tirapazamine, 3-amino-1,2,4-benzotriazine-1,4-dioxide). The anti-tumour effect of AQ4N was potentiated in vivo by combination with hypobaric hypoxia with a dose enhancement ratio of 5.1. This is consistent with the proposal that AQ4N was reduced in vivo to AQ4, resulting in enhanced anti-tumour toxicity. When AQ4N (200 mg kg-1) was combined with single dose radiation (12 Gy) the drug was shown to have an additive interaction with radiation. This was obtained even if the drug was administered from 4 days before to 6 h after radiation treatment. Equivalent anti-tumour activity was also shown when both AQ4N (200 mg kg-1) and radiation (5 x 3 Gy) were administered in fractionated schedules. In conclusion, AQ4N shows significant potential as a bioreductive drug for combination with fractionated radiotherapy.

Full text

PDF
76

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bremner J. C., Stratford I. J., Bowler J., Adams G. E. Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer. 1990 May;61(5):717–721. doi: 10.1038/bjc.1990.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bush R. S., Jenkin R. D., Allt W. E., Beale F. A., Bean H., Dembo A. J., Pringle J. F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl. 1978 Jun;3:302–306. [PMC free article] [PubMed] [Google Scholar]
  3. Cole S., Stratford I. J., Bowler J., Nolan J., Wright E. G., Lorimore S. A., Adams G. E. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice. Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):387–395. doi: 10.1016/0360-3016(91)90787-5. [DOI] [PubMed] [Google Scholar]
  4. Denny W. A., Wakelin L. P. Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumour activity. Anticancer Drug Des. 1990 May;5(2):189–200. [PubMed] [Google Scholar]
  5. Faulds D., Balfour J. A., Chrisp P., Langtry H. D. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991 Mar;41(3):400–449. doi: 10.2165/00003495-199141030-00007. [DOI] [PubMed] [Google Scholar]
  6. Grau C., Overgaard J. Radiosensitizing and cytotoxic properties of mitomycin C in a C3H mouse mammary carcinoma in vivo. Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):265–269. doi: 10.1016/0360-3016(91)90102-a. [DOI] [PubMed] [Google Scholar]
  7. Koch C. J. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. 1993 Sep 1;53(17):3992–3997. [PubMed] [Google Scholar]
  8. Krupski G., Kiefer F., Wiebel F. J. Variability in the expression of xenobiotic-metabolizing enzymes during the growth cycle of rat hepatoma cells. Xenobiotica. 1985 Aug-Sep;15(8-9):781–787. doi: 10.3109/00498258509047441. [DOI] [PubMed] [Google Scholar]
  9. McAleer J. J., McKeown S. R., MacManus M. P., Lappin T. R., Bridges J. M. Hypobaric hypoxia: a method for testing bioreductive drugs in vivo. Int J Radiat Oncol Biol Phys. 1992;23(3):551–555. doi: 10.1016/0360-3016(92)90010-f. [DOI] [PubMed] [Google Scholar]
  10. Minchinton A. I., Brown J. M. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing. Br J Cancer. 1992 Dec;66(6):1053–1058. doi: 10.1038/bjc.1992.409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Moore J. V. The dynamics of tumor cords in an irradiated mouse mammary carcinoma with a large hypoxic cell component. Jpn J Cancer Res. 1988 Feb;79(2):236–243. doi: 10.1111/j.1349-7006.1988.tb01582.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Patterson L. H. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev. 1993 Jun;12(2):119–134. doi: 10.1007/BF00689805. [DOI] [PubMed] [Google Scholar]
  13. Trotter M. J., Chaplin D. J., Olive P. L. Possible mechanisms for intermittent blood flow in the murine SCCVII carcinoma. Int J Radiat Biol. 1991 Jul-Aug;60(1-2):139–146. doi: 10.1080/09553009114551731. [DOI] [PubMed] [Google Scholar]
  14. Workman P., Stratford I. J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 1993 Jun;12(2):73–82. doi: 10.1007/BF00689802. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES